CPRX - Catalyst Pharmaceuticals GAAP EPS of $0.09 misses by $0.03 revenue of $38.31M beats by $0.13M

Catalyst Pharmaceuticals press release (NASDAQ:CPRX): Q4 GAAP EPS of $0.09 misses by $0.03. Revenue of $38.31M (+23.5% Y/Y) beats by $0.13M. Shares -0.13%. Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity. New Patent Issuances Strengthens FIRDAPSE Long-Term Commercial Potential to 2034. Actively Pursuing Opportunities to Diversify Commercial and Development Portfolio. Strong Cash and Investments Position of $191 Million and No Funded Debt.

For further details see:

Catalyst Pharmaceuticals GAAP EPS of $0.09 misses by $0.03, revenue of $38.31M beats by $0.13M